PALISADE BIO INC (PALI) Stock Price, Quote, News and Overview
NASDAQ:PALI - Nasdaq - US6963894026 - Common Stock - Currency: USD
PALI Quote, Performance and Key Statistics
0.613
-0.03 (-4.23%)
The current stock price of PALI is 0.613 USD. In the past month the price decreased by -10.75%. In the past year, price decreased by -87.26%.
PALI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.58 | 337.14B | ||
| AMGN | AMGEN INC | 14.24 | 158.93B | ||
| GILD | GILEAD SCIENCES INC | 14.32 | 137.86B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 115.79B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.8 | 56.43B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.26B | ||
| ARGX | ARGENX SE - ADR | 95.86 | 33.66B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.76 | 28.60B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.56B | ||
| NTRA | NATERA INC | N/A | 22.97B | ||
| BIIB | BIOGEN INC | 8.28 | 19.20B | ||
| INSM | INSMED INC | N/A | 18.50B |
Related stock screener links
About PALI
Company Profile
Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. The company is headquartered in Carlsbad, California and currently employs 8 full-time employees. The company went IPO on 2006-12-20. The firm is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The firm is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. The company utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.
Company Info
PALISADE BIO INC
7750 El Camino Real, Suite 5200
Carlsbad CALIFORNIA 20876 US
CEO: Kenneth Carter
Employees: 8
Phone: 18587044900
PALISADE BIO INC / PALI FAQ
What is the stock price of PALISADE BIO INC today?
The current stock price of PALI is 0.613 USD. The price decreased by -4.23% in the last trading session.
What is the ticker symbol for PALISADE BIO INC stock?
The exchange symbol of PALISADE BIO INC is PALI and it is listed on the Nasdaq exchange.
On which exchange is PALI stock listed?
PALI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PALISADE BIO INC stock?
9 analysts have analysed PALI and the average price target is 10.88 USD. This implies a price increase of 1674.88% is expected in the next year compared to the current price of 0.613. Check the PALISADE BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PALISADE BIO INC worth?
PALISADE BIO INC (PALI) has a market capitalization of 2.94M USD. This makes PALI a Nano Cap stock.
How many employees does PALISADE BIO INC have?
PALISADE BIO INC (PALI) currently has 8 employees.
What are the support and resistance levels for PALISADE BIO INC (PALI) stock?
PALISADE BIO INC (PALI) has a resistance level at 0.75. Check the full technical report for a detailed analysis of PALI support and resistance levels.
Should I buy PALISADE BIO INC (PALI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PALI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PALI, evaluating the profitability, health, valuation and growth aspects
- PALISADE BIO INC (PALI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PALISADE BIO INC (PALI) Sales and EPS estimates to see what analysts future expectations are.
- PALISADE BIO INC (PALI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PALISADE BIO INC (PALI) Insider and Institutional Ownership to learn about the owners and their transactions.
- PALISADE BIO INC (PALI) Stock Chart to make your own analysis
- PALISADE BIO INC (PALI) Latest news and press-releases to stay up to date.
Does PALISADE BIO INC (PALI) stock pay dividends?
PALI does not pay a dividend.
When does PALISADE BIO INC (PALI) report earnings?
PALISADE BIO INC (PALI) will report earnings on 2025-08-11.
What is the Price/Earnings (PE) ratio of PALISADE BIO INC (PALI)?
PALISADE BIO INC (PALI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.66).
What is the Short Interest ratio of PALISADE BIO INC (PALI) stock?
The outstanding short interest for PALISADE BIO INC (PALI) is 3.67% of its float. Check the ownership tab for more information on the PALI short interest.
PALI Technical Analysis
PALI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PALI. PALI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
PALI Financial Highlights
Over the last trailing twelve months PALI reported a non-GAAP Earnings per Share(EPS) of -7.66. The EPS increased by 70.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -132.7% | ||
| ROE | -192.71% | ||
| Debt/Equity | 0 |
PALI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to PALI. The Buy consensus is the average rating of analysts ratings from 9 analysts.